NEW YORK--(BUSINESS WIRE)--Enzo Biochem Inc. (NYSE:ENZ) today reported improved results for the fiscal quarter ended January 31, 2012. Among the quarter’s highlights:
Total revenues increased 5% year over year, led by strong organic growth at Enzo Clinical Labs and increased royalty and licensee income
